Physician profile
Scott Sobieraj
NPI 1730333592
$2,687.66
in general payments reported to CMS, 2019-2025
27 companies · $373 in 2025
The $373 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $170 · 2021: $526 · 2022: $277 · 2023: $362 · 2024: $432 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.69 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $389.95 | 2019-2025 | |
| Amgen INC. | $310.47 | 2019-2022 | |
| Medtronic, INC. | $190.70 | 2023-2024 | Micra |
| Pfizer INC. | $144.37 | 2021-2025 | |
| Abbott Laboratories | $143.95 | 2024-2025 | Cardiomems, Freestyle Libre 3 |
| Biotronik INC. | $138.70 | 2019-2023 | Biomonitor |
| Boston Scientific Corporation | $114.18 | 2022-2025 | Farapulse, Lux-Dx Insertable Cardiac Monitor |
| Janssen Pharmaceuticals, INC | $104.54 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $98.59 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.41 | 2019-2024 | Lifevest |
| Gilead Sciences, INC. | $63.79 | 2019-2025 | |
| Astellas Pharma US INC | $59.76 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $53.06 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.58 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.03 | 2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $39.77 | 2024 | Wegovy |
| Sanofi-Aventis U.S. LLC | $37.12 | 2019-2021 | |
| Cvrx, INC. | $29.14 | 2024 | Barostim Neo System |
| Nevro Corp. | $29.03 | 2024 | Senza |
| Mannkind Corporation | $24.12 | 2024 | |
| Smith+Nephew, INC. | $24.07 | 2024 | Or3o Dual Mobility, Real Intelligence |
| Kowa Pharmaceuticals America, INC. | $20.21 | 2025 | Zoryve |
| Lantheus Medical Imaging, INC. | $19.02 | 2021 | |
| Exact Sciences Corporation | $14.75 | 2024 | Cologuard Collection Kit |
| Akcea Therapeutics, INC. | $13.69 | 2020 | |
| Amarin Pharma, INC. | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Sobieraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.